{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-095275","form_type":"8-K","ticker":"MNOV","cik":"0001226616","company_name":"MEDICINOVA INC","filed_at":"2022-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.981168+00:00","generated_at":"2026-06-26T09:20:41.058645+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit","bullets":["Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.","MediciNova, as successor to Avigen, assigned patents to Genzyme in 2005 and may receive a portion of any damages recovered.","Lawsuit targets unauthorized use of rAAV vectors for gene therapy drug Zolgensma.","No guarantee of payment; contingent on Genzyme's recovery via settlement or judgment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-095275","json":"https://secwatch.observer/filing/0001193125-22-095275.json","markdown":"https://secwatch.observer/filing/0001193125-22-095275.md","text":"https://secwatch.observer/filing/0001193125-22-095275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1226616/000119312522095275/0001193125-22-095275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1226616/000119312522095275/d681432d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:20:41.058645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}